人附睾蛋白4作为卵巢癌生物标志物的初步研究

A Study on HE4 as a Biomarker in Ovarian Carcinoma

目的:探讨人附睾蛋白4(HE4)在卵巢癌组织和血清中的表达及其临床病理意义。方法:用免疫组织化学技术检测正常卵巢,卵巢良性上皮性肿瘤,交界性上皮性肿瘤和癌组织中HE4的表达,并分析其与临床分期和预后的关系;用ELISA方法检测患者血清中HE4的含量。结果:HE4在浆液性乳头状囊腺癌组织中的阳性表达率要显著高于交界性肿瘤,良性肿瘤和正常组织,而交界性肿瘤阳性表达率显著高于良性肿瘤和正常对照。HE4表达与临床分期没有显著相关性。HE4阳性患者的平均生存期、5年生存率和中位生存期均显著低于HE4阴性患者。卵巢癌和交界性肿瘤患者血清中HE4含量显著高于良性肿瘤和正常对照组。结论:HE4可能作为卵巢癌诊断和预后的组织和血清标志物。

Objective： To investigate the expression of HE4 in ovarian carcinoma and its clinical significance. Methods： HFA expres-sion in ovarian carcinoma, borderline ovarian epithelial neoplasm, benign ovarian Epithelial neoplasm, normal ovarian was investigated by immunohistochemical method. And relation to clinical stage and prognosis. The HE4 serum level in ovarian neoplasm was assayed by ELISA. Results： HE4 positive rate in Serous cystadenocarcinoma was higher than borderline serous cystadenoma, serous cystadenoma and normal ovarian tissue, and HE4 positive rate in borderline serous cystadenoma was higher than serous cystadenoma and normal ovarian tissue. HE4 expression was not related to clinical stage of ovarian carcinoma. Average survival, five-years survival rate and medium survival span of the patients with HE4 expression were lower than those without HE4 expression. HE4 serum level in borderline serous cystade-noma and serous cystadenocarcinoma was higher than serous cystadenoma and normal ovarian tissue. Conclusion： HE4 may act as a serum and tissue biomarker for diagnosis and prognosis in ovarian carcinoma.